- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07323654
En studie av KT-621 administrert oralt til voksne deltakere med moderat til alvorlig eosinofil astma (BREADTH)
En fase 2b, randomisert, dobbeltblind, placebo-kontrollert, parallellgruppe, multisenter, doseringsstudie som undersøker effektiviteten og sikkerhetsprofilen til KT-621 administrert oralt til voksne deltakere med ukontrollert moderat til alvorlig eosinofil astma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Kymera Medical Director
- Telefonnummer: 857-285-5300
- E-post: clinicaltrials@kymeratx.com
Studiesteder
-
-
-
Buenos Aires, Argentina
- Rekruttering
- Kymera Investigative Site
-
Concepción del Uruguay, Argentina
- Rekruttering
- Kymera Investigative Site
-
Lobos, Argentina
- Rekruttering
- Kymera Investigative Site
-
Mar del Plata, Argentina
- Rekruttering
- Kymera Investigative Site
-
Quilmes, Argentina
- Rekruttering
- Kymera Investigative Site
-
Rosario, Argentina
- Rekruttering
- Kymera Investigative Site
-
San Miguel de Tucumán, Argentina
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Brussels, Belgia
- Rekruttering
- Kymera Investigative Site
-
Erpent, Belgia
- Rekruttering
- Kymera Investigative Site
-
Ghent, Belgia
- Rekruttering
- Kymera Investigative Site
-
Liège, Belgia
- Rekruttering
- Kymera Investigative Site
-
-
-
-
California
-
Lancaster, California, Forente stater, 93534
- Rekruttering
- Kymera Investigative Site
-
Long Beach, California, Forente stater, 90815
- Rekruttering
- Kymera Investigative Site
-
Northridge, California, Forente stater, 91324
- Rekruttering
- Kymera Investigative Site
-
Redding, California, Forente stater, 96001
- Rekruttering
- Kymera Investigative Site
-
San Francisco, California, Forente stater, 94112
- Rekruttering
- Kymera Investigative Site
-
Upland, California, Forente stater, 91786
- Rekruttering
- Kymera Investigative Site
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- Kymera Investigative Site
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06519
- Rekruttering
- Kymera Investigative Site
-
-
Florida
-
Loxahatchee Groves, Florida, Forente stater, 33470
- Rekruttering
- Kymera Investigative Site
-
Miami, Florida, Forente stater, 33126
- Rekruttering
- Kymera Investigative Site
-
Miami, Florida, Forente stater, 33173
- Rekruttering
- Kymera Investigative Site
-
Miami Lakes, Florida, Forente stater, 33014
- Rekruttering
- Kymera Investigative Site
-
Orlando, Florida, Forente stater, 32819
- Rekruttering
- Kymera Investigative Site
-
Tampa, Florida, Forente stater, 33607
- Rekruttering
- Kymera Investigative Site
-
-
Georgia
-
East Point, Georgia, Forente stater, 30344
- Rekruttering
- Kymera Investigative Site
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- Kymera Investigative Site
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Rekruttering
- Kymera Investigative Site
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40217
- Rekruttering
- Kymera Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Kymera Investigative Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27517
- Rekruttering
- Kymera Investigative Site
-
Durham, North Carolina, Forente stater, 27705
- Rekruttering
- Kymera Investigative Site
-
-
Ohio
-
Toledo, Ohio, Forente stater, 43617
- Rekruttering
- Kymera Investigative Site
-
-
Oklahoma
-
Edmond, Oklahoma, Forente stater, 73034
- Rekruttering
- Kymera Investigative Site
-
-
Oregon
-
Clackamas, Oregon, Forente stater, 97015
- Rekruttering
- Kymera Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19140
- Rekruttering
- Kymera Investigative Site
-
Pittsburgh, Pennsylvania, Forente stater, 15241
- Rekruttering
- Kymera Investigative Site
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Rekruttering
- Kymera Investigative Site
-
-
South Carolina
-
North Charleston, South Carolina, Forente stater, 29406
- Rekruttering
- Kymera Investigative Site
-
Rock Hill, South Carolina, Forente stater, 29732
- Rekruttering
- Kymera Investigative Site
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37403
- Rekruttering
- Kymera Investigative Site
-
-
Texas
-
Dallas, Texas, Forente stater, 75209
- Rekruttering
- Kymera Investigative Site
-
Dallas, Texas, Forente stater, 75246
- Rekruttering
- Kymera Investigative Site
-
McKinney, Texas, Forente stater, 75069
- Rekruttering
- Kymera Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Rome, Italia
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Bialystok, Polen
- Rekruttering
- Kymera Investigative Site
-
Gdansk, Polen
- Rekruttering
- Kymera Investigative Site
-
Lodz, Polen
- Rekruttering
- Kymera Investigative Site
-
Poznan, Polen
- Rekruttering
- Kymera Investigative Site
-
Sosnowiec, Polen
- Rekruttering
- Kymera Investigative Site
-
Tarnów, Polen
- Rekruttering
- Kymera Investigative Site
-
Trzebnica, Polen
- Rekruttering
- Kymera Investigative Site
-
Wroclaw, Polen
- Rekruttering
- Kymera Investigative Site
-
Zawadzkie, Polen
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Brasov, Romania
- Rekruttering
- Kymera Investigative Site
-
Craiova, Romania
- Rekruttering
- Kymera Investigative Site
-
Timișoara, Romania
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Rekruttering
- Kymera Investigative Site
-
Belgrade, Serbia
- Rekruttering
- Kymera Investigative Site
-
Kamenitz, Serbia, 21204
- Rekruttering
- Kymera Investigative Site
-
Užice, Serbia, 31000
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Bardejov, Slovakia
- Rekruttering
- Kymera Investigative Site
-
Košice, Slovakia
- Rekruttering
- Kymera Investigative Site
-
Spišská Nová Ves, Slovakia
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Cadiz, Spania
- Rekruttering
- Kymera Investigative Site
-
Jerez de la Frontera, Spania
- Rekruttering
- Kymera Investigative Site
-
Madrid, Spania
- Rekruttering
- Kymera Investigative Site
-
Mataró, Spania
- Rekruttering
- Kymera Investigative Site
-
Santander, Spania
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Bedford, Storbritannia, MK40 2FG
- Rekruttering
- Kymera Investigative Site
-
Birmingham, Storbritannia
- Rekruttering
- Kymera Investigative Site
-
Bristol, Storbritannia
- Rekruttering
- Kymera Investigative Site
-
Leicester, Storbritannia
- Rekruttering
- Kymera Investigative Site
-
London, Storbritannia
- Rekruttering
- Kymera Investigative Site
-
Wythenshawe, Storbritannia
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Gyeonggi-do, Sør -Korea
- Rekruttering
- Kymera Investigative Site
-
Seoul, Sør -Korea
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Berlin, Tyskland
- Rekruttering
- Kymera Investigative Site
-
Leipzig, Tyskland
- Rekruttering
- Kymera Investigative Site
-
-
-
-
-
Vienna, Østerrike
- Rekruttering
- Kymera Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Must be 18 years old (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age, inclusive, at the time of signing the ICF.
- Must have a physician diagnosis of asthma for at least 1 year prior to the Screening visit.
- Must be on a stable regimen of medium- to high- dose inhaled corticosteroid (ICS), in combination with a long-acting β2-agonist (LABA). The regimen may include additional controller medications used for at least 12 weeks, at a stable dose and regimen, with no change in the dose or frequency of administration for at least 4 weeks prior to the Screening visit and between the Screening and Baseline visits.
- Must have a pre-bronchodilator FEV1 40 to 80% of predicted normal at the Screening and Baseline visits, prior to randomization.
- Must have an ACQ-5 score ≥ 1.5 at the Screening and Baseline visits, prior to randomization.
- Must have a FeNO level of ≥ 25 ppb at the Screening and Baseline visits.
- Must have a demonstrated evidence of reversible airway obstruction by post-bronchodilator (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL at Screening.
- Must have an absolute blood eosinophil count must be ≥ 0.30 × 10^9/L at Screening.
- Must have a documented history of at least 1 asthma exacerbation requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening within the past 52 weeks prior to Screening.
- Must agree to contraceptive requirements in compliance with the clinical study and local requirements.
- Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
Exclusion Criteria:
- Must not have any clinically significant pulmonary disease other than asthma.
- Must not have had an asthma exacerbation, requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening, at any time from 4 weeks prior to the Screening visit up to and including the Baseline visit.
- Must not have any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, study evaluations, and/or study procedures.
- Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.
- Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.
- Must not have been dosed with any investigational drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.
- Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
- Must not be a current smoker of nicotine/tobacco as well as non-nicotine products, have a smoking history of ≥ 10 pack years, or use vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack years and users of vaping or e-cigarette products must have stopped for at least 26 weeks prior to the Screening visit.
- Must not have a known sensitivity to any of the components of KT-621.
- Must not be a member of the investigational team or his/her immediate family.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Gruppe 1: KT-621 Dose 1
|
Oral drug |
|
Eksperimentell: Gruppe 2: KT-621 Dose 2
|
Oral drug |
|
Eksperimentell: Gruppe 3: KT-621 Dose 3
|
Oral drug |
|
Placebo komparator: Gruppe 4: Placebo
|
Oral placebo matched to KT-621 |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Endring fra utgangspunkt i pre-bronkodilator FEV1
Tidsramme: Fra baseline til uke 12
|
Fra baseline til uke 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Endring fra utgangspunkt i post-bronkodilator FEV1
Tidsramme: Fra baseline til uke 12
|
Fra baseline til uke 12
|
|
Endring fra utgangspunkt i Asthma Control Questionnaire 5-spørsmåls versjon (ACQ-5) score
Tidsramme: Fra baseline til uke 12
|
Fra baseline til uke 12
|
|
Endring fra utgangspunkt i Standardisert Astma Livskvalitet Spørreskjema [AQLQ(S)] Global Score
Tidsramme: Fra baseline til uke 12
|
Fra baseline til uke 12
|
|
Forekomst av behandlingsrelaterte bivirkninger (TEAEs)
Tidsramme: Fra baseline gjennom uke 16
|
Fra baseline gjennom uke 16
|
|
Forekomst av behandlingsrelaterte alvorlige bivirkninger (SAE-er)
Tidsramme: Fra baseline gjennom uke 16
|
Fra baseline gjennom uke 16
|
|
Plasmakonsentrasjon av KT-621 avledet fra plasmakonsentrasjon-tidsdata
Tidsramme: Fra utgangspunkt til uke 16
|
Fra utgangspunkt til uke 16
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- KT621-AS-202
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .